Godbersen, Godber Mathis http://orcid.org/0000-0002-9739-0724
Falb, Pia http://orcid.org/0000-0003-4817-3499
Klug, Sebastian http://orcid.org/0000-0001-8714-6608
Silberbauer, Leo R. http://orcid.org/0000-0002-8521-1012
Reed, Murray Bruce http://orcid.org/0000-0002-4873-608X
Nics, Lukas http://orcid.org/0000-0002-1034-876X
Hacker, Marcus http://orcid.org/0000-0002-4222-4083
Lanzenberger, Rupert http://orcid.org/0000-0003-4641-9539
Hahn, Andreas http://orcid.org/0000-0001-9727-7580
Funding for this research was provided by:
Austrian Science Fund (KLI 610, KLI516, KLI 1006)
Medical University of Vienna (MDPhD Excellence Program, MDPhD Excellence Program)
Österreichischen Akademie der Wissenschaften (DOC fellowship, DOC fellowship)
Medical University of Vienna
Article History
Received: 21 November 2023
Accepted: 2 March 2024
First Online: 16 March 2024
Declarations
:
: Both studies were approved by the Ethics Committee of the Medical University of Vienna (ethics numbers DS1: 1479/2015 and DS2: 1916/2013). Procedures were carried out in agreement with the Declaration of Helsinki. The study related to DS1 has been registered at ClinicalTrials.com (clinical trials identifier: NCT03485066).
: All participants gave their written informed consent for participation after extensive instruction about the respective study’s protocol.
: RL received investigator-initiated research funding from Siemens Healthcare regarding clinical research using PET/MR. He is a shareholder of the start-up company BM Health GmbH since 2019. M. Hacker received consulting fees and/or honoraria from Bayer Healthcare BMS, Eli Lilly, EZAG, GE Healthcare, Ipsen, ITM, Janssen, Roche, and Siemens Healthineers. All other authors report no conflict of interest in relation to this study.